<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antileukotriene agents in the management of asthma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antileukotriene agents in the management of asthma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antileukotriene agents in the management of asthma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joshua A Boyce, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce S Bochner, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Leukotrienes are powerful lipid mediators of inflammation generated principally by myeloid cells and mucosal chemosensory cells. Their name derives from their cells of origin (leukocytes) and a positionally conserved triad of double bonds (triene). The potency of the leukotrienes and their production during inflammatory responses, including the airway inflammation of asthma, made them a promising molecular target for therapeutic development.</p><p>This topic reviews the biology of the leukotrienes, their role in asthma and inflammation, and the use of 5-lipoxygenase (5-LO) inhibitors and cysteinyl leukotriene (CysLT) receptor antagonists as treatments for asthma, rhinitis, and other allergic diseases. An overview of asthma management and the integrated use of asthma therapies are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">LEUKOTRIENE BIOLOGY</span></p><p class="headingAnchor" id="H4133797237"><span class="h2">Synthesis</span><span class="headingEndMark"> — </span>Arachidonic acid is a 20-carbon polyunsaturated fatty acid liberated by activated cells and is the substrate from which both leukotrienes and prostaglandins are generated. In myeloid cells, a substantial fraction of released arachidonate is presented by the membrane-bound 5-lipoxygenase-activating protein (FLAP) [<a href="#rid1">1</a>] to 5-lipoxygenase (5-LO), an enzyme that translocates to the nuclear membrane to catalyze the formation of leukotriene A<sub>4</sub> (LTA<sub>4</sub>)  (<a class="graphic graphic_figure graphicRef75064" href="/z/d/graphic/75064.html" rel="external">figure 1</a>) [<a href="#rid2">2</a>]. LTA<sub>4</sub> is an unstable epoxide, which depending upon the cell type of origin, is either hydrolyzed by a specific LTA<sub>4</sub> hydrolase (LTA<sub>4</sub>H) [<a href="#rid3">3</a>] to form LTB<sub>4</sub>, a potent chemoattractant for neutrophils and some T cell populations [<a href="#rid4">4</a>], or is conjugated to reduced glutathione by membrane-bound leukotriene C<sub>4</sub> synthase (LTC<sub>4</sub>S) [<a href="#rid5">5</a>] to form LTC<sub>4</sub>. LTC<sub>4</sub> is the parent molecule of the cysteinyl leukotrienes (CysLTs). CysLTs are a potent class of bronchoconstrictors and activators of innate immune effector cells [<a href="#rid6">6</a>] and have a validated role in asthma.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>LTB</strong><strong><sub>4</sub></strong> – The roles of LTB<sub>4 </sub>and<sub> </sub>its receptor in asthma are not clear. LTB<sub>4</sub> is the dominant 5-LO pathway product of neutrophils [<a href="#rid7">7</a>] and is also generated by macrophages [<a href="#rid8">8</a>] and mast cells [<a href="#rid9">9</a>]. One study suggested a weak capacity of eosinophils from patients with severe asthma to generate LTB<sub>4</sub> as well [<a href="#rid10">10</a>]. Once converted by LTA<sub>4</sub>H, LTB<sub>4</sub> is released to the extracellular space, where it exerts its actions at two different G protein coupled receptors (GPCRs), termed BLT<sub>1</sub> and BLT<sub>2</sub>, respectively [<a href="#rid11">11,12</a>]. LTB<sub>4</sub> is a potent chemoattractant for neutrophils in both humans and in mice [<a href="#rid13">13</a>]. It is also chemotactic for populations of CD4+ [<a href="#rid4">4,14</a>] and CD8+ effector memory cells [<a href="#rid15">15</a>], including a population of interleukin (IL)-13-expressing CD8+ cells that are present in the airways of patients with severe asthma [<a href="#rid16">16</a>]. Studies using gene-deleted mice and selective receptor antagonists suggest that BLT<sub>1</sub> is the dominant receptor for LTB<sub>4</sub> in mediating chemotaxis of leukocytes and suggest that this receptor may be involved in facilitating eosinophilic airway pathology [<a href="#rid15">15</a>]. Although LTB<sub>4</sub> can be detected in the bronchoalveolar lavage fluid from severely asthmatic subjects [<a href="#rid17">17</a>], no studies have yet addressed the role of LTB<sub>4</sub> or BLT<sub>1</sub> receptors in asthma due to a lack of approved receptor antagonists.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CysLTs</strong> – Mast cells, eosinophils, and basophils, the principal effector cells of type 2 (eosinophil-rich) immunopathology, all express LTC<sub>4</sub>S, and they preferentially or exclusively generate LTC<sub>4</sub> rather than LTB<sub>4</sub> when activated [<a href="#rid18">18-20</a>]. Macrophages and myeloid dendritic cells also express LTC<sub>4</sub>S [<a href="#rid21">21,22</a>], as do platelets [<a href="#rid23">23</a>]. Platelets lack FLAP and 5-LO but can convert LTA<sub>4</sub> from granulocytes to LTC<sub>4</sub>, especially during inflammatory responses when they often form P-selectin-dependent complexes with granulocytes in the peripheral circulation [<a href="#rid24">24</a>]. In asthma, the frequencies of these platelet-leukocyte complexes are higher than in nonasthmatic controls [<a href="#rid25">25</a>] and are markedly increased in the blood and sinonasal tissues of patients with aspirin-exacerbated respiratory disease (AERD; a clinical triad of asthma, nasal polyps, and pathognomonic respiratory reactions to the ingestion of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and other nonselective inhibitors of cyclooxygenase, which is associated with especially high levels of CysLT production) [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a>.)</p><p></p><p class="bulletIndent1">Although most nonhematopoietic cells cannot generate leukotrienes, specialized populations of rare chemosensory cells in the intestine (tuft cells) and in the airway (brush cells) express FLAP, 5-LO, and LTC<sub>4</sub>S and generate substantial quantities of LTC<sub>4</sub> on a per cell basis when activated [<a href="#rid26">26,27</a>]. The diverse cell sources of LTC<sub>4</sub> imply complex functions that vary depending on context. Once released, LTC<sub>4</sub> is converted by a gamma glutamyl leukotrienase to LTD<sub>4</sub> by removal of the glutamic acid residue from the glutathione adduct [<a href="#rid28">28</a>]. LTD<sub>4</sub> is extremely short lived due to its rapid conversion by extracellular dipeptidases to the stable metabolite, LTE<sub>4</sub>, by removal of glycine [<a href="#rid29">29</a>]. LTE<sub>4</sub> is excreted in the urine without further modification [<a href="#rid30">30</a>] and is often used a marker of systemic production of CysLTs in clinical studies [<a href="#rid31">31,32</a>].</p><p></p><p class="bulletIndent1">All three CysLTs are bioactive mediators, stimulating three different cognate GPCRs that differ in ligand preference and distribution of expression [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The type 1 CysLT receptor (CysLT<sub>1</sub>R) is the target of the available receptor antagonists approved for the treatment of asthma and allergic rhinitis [<a href="#rid34">34,35</a>]. It has high affinity for LTD<sub>4</sub> and is expressed by airway and vascular smooth muscle and several immune cells [<a href="#rid36">36-38</a>]. CysLT<sub>1</sub>R is responsible for the bronchoconstricting effects of the CysLTs in human subjects, as well as the activation of certain relevant immune cells (mast cells, innate group 2 lymphoid cells, T helper type 2 [Th2] cells) [<a href="#rid39">39-43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CysLT<sub>2</sub>R, expressed by endothelial cells, brain, cardiac Purkinje cells, and leukocytes, recognizes LTC<sub>4</sub> and LTD<sub>4 </sub>with equal affinity [<a href="#rid44">44</a>], while CysLT<sub>3</sub>R (also known as GPR99) is expressed by epithelial cells of the airway and proximal convoluted tubule [<a href="#rid45">45,46</a>]. Although animal models suggest that CysLT<sub>2</sub>R and CysLT<sub>3</sub>R both play important roles in allergic pulmonary inflammation [<a href="#rid47">47,48</a>], knowledge of their role in human asthma is limited by the absence of selectively targeted drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variations in leukotriene synthesis</strong> – Human subjects display a wide range of variability in leukotriene pathway activity, likely reflecting genetic, microenvironmental, and hormonal influences. Leukocytes from female subjects generate higher quantities of leukotrienes than do those from male subjects, presumably reflecting the ability of androgens to suppress the assembly of leukotriene synthetic enzymes [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">Polymorphic variants in either the coding or the promoter regions of 5-LO, FLAP, LTA<sub>4</sub> hydrolase, and LTC<sub>4</sub>S may affect enzyme expression and function [<a href="#rid50">50-53</a>]. A 5-LO promoter polymorphism predicts the therapeutic response to the 5-LO inhibitor <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a>. A common promoter polymorphism in t<em>he LTC4S</em> gene may increase the expression of this enzyme and is associated with increased LTC<sub>4</sub> synthesis by eosinophils ex vivo [<a href="#rid54">54</a>]. This polymorphism was originally reported as a risk allele for AERD [<a href="#rid53">53</a>], although subsequent studies failed to replicate this association [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1">Bronchial biopsies from patients with AERD display sharply increased expression of LTC<sub>4</sub>S protein that localizes to eosinophils [<a href="#rid56">56</a>] and correlates with the severity of reactions to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge. Additionally, blood and sinonasal tissue granulocytes from patients with AERD show sharply increased percentages of adherent LTC<sub>4</sub>S-expressing platelets [<a href="#rid23">23</a>]. IL-4, a key cytokine involved in type 2 immunity, potently upregulates the expression of LTC<sub>4</sub>S by mast cells and dramatically enhances their capacity to generate LTC<sub>4</sub> when activated [<a href="#rid57">57</a>]. IL-5 elicits the translocation of 5-LO to the nucleus of human eosinophils [<a href="#rid58">58</a>] and mast cells [<a href="#rid57">57</a>], priming them for augmented agonist-induced LTC<sub>4</sub> production. Collectively, these findings suggest a complex regulation of leukotriene pathway activity in human subjects. Individual variations in CysLT production (expressed as a ratio of urinary LTE<sub>4</sub> to exhaled nitric oxide levels) are reported to predict response to CysLT<sub>1</sub>R antagonists [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Functions of leukotrienes relevant to asthma pathogenesis</span></p><p class="headingAnchor" id="H827334170"><span class="h3">Bronchoconstriction</span><span class="headingEndMark"> — </span>CysLTs are the most powerful bronchoconstrictors known to exist. LTC<sub>4</sub> and LTD<sub>4</sub> exceed the potencies of histamine and <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> by approximately 1000-fold [<a href="#rid60">60,61</a>]. Asthmatic and nonasthmatic subjects display similar degrees of airway sensitivity to LTC<sub>4</sub> and LTD<sub>4</sub> [<a href="#rid61">61,62</a>], which elicit constriction directly through airway smooth muscle-associated CysLT<sub>1</sub>R.</p><p>Supporting the physiologic importance of CysLTs as bronchoconstrictors in asthma, CysLT<sub>1</sub>R inhibitors reduce bronchoconstriction, as shown in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In atopic asthmatic subjects, the selective CysLT<sub>1</sub>R antagonist pranlukast (available in Japan) attenuates the decline in forced expiratory volume in one second (FEV<sub>1</sub>) induced by inhalation challenges with specific allergens by approximately 50 percent [<a href="#rid63">63</a>], and it also blocks bronchoconstriction elicited by exercise [<a href="#rid64">64</a>], cold air [<a href="#rid65">65</a>], and inhalations of adenosine [<a href="#rid66">66</a>] or <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a> [<a href="#rid67">67</a>], all of which elicit LTC<sub>4</sub> synthesis in vivo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with asthma presenting to the emergency department with exacerbations display increased levels of urinary LTE<sub>4</sub>  (<a class="graphic graphic_figure graphicRef68872" href="/z/d/graphic/68872.html" rel="external">figure 2</a>) [<a href="#rid68">68</a>]. Intravenously administered <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, another selective CysLT<sub>1</sub>R antagonist, significantly increased peak expiratory flow in emergency department patients presenting with asthma attacks, although it failed to alter discharge rates [<a href="#rid69">69,70</a>].</p><p></p><p>Patients with asthma display selectively enhanced sensitivity to LTE<sub>4</sub>-induced bronchoconstriction compared with nonasthmatic controls [<a href="#rid71">71</a>], even though LTE<sub>4</sub> is a less potent constrictor than its precursors (likely reflecting its weak binding affinity for CysLT<sub>1</sub>R) [<a href="#rid36">36,72</a>]. Subjects with AERD, display even greater degrees of LTE<sub>4</sub> hyperresponsiveness than do <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> tolerant asthmatic subjects [<a href="#rid73">73,74</a>] without differences in reactivity to histamine or LTC<sub>4</sub>.</p><p>The basis for selective LTE<sub>4</sub> hyperresponsiveness is unknown but could reflect increased numbers of receptors or increased numbers of LTE<sub>4</sub>-responsive cell types. The numbers of CysLT<sub>1</sub>R-expressing cells in the airways of subjects with AERD exceed those observed in aspirin-tolerant asthmatic controls [<a href="#rid75">75,76</a>]. Notably, therapeutic desensitization to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, a procedure that improves disease control in many subjects with AERD, sharply reduces CysLT<sub>1</sub>R expression in sinonasal tissues [<a href="#rid75">75</a>] and elicits a loss of end-organ LTE<sub>4</sub> hyperresponsiveness [<a href="#rid74">74</a>]. This may explain why asthma frequently improves in patients with AERD after desensitization to aspirin [<a href="#rid77">77</a>], despite substantially increased levels of urinary LTE<sub>4</sub> compared with pretreatment levels [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a> and  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization"</a>.)</p><p class="headingAnchor" id="H383455421"><span class="h3">Mucus secretion</span><span class="headingEndMark"> — </span>Studies of mucus secretion provide evidence for the presence of a third CysLT receptor (CysLT<sub>3</sub>R), in addition to CysLT<sub>1</sub>R and CysLT<sub>2</sub>R, and for a role of platelets in LTE<sub>4</sub>-induced mucin elaboration. Both LTC<sub>4</sub> and LTD<sub>4</sub> elicit the release of mucus from human bronchi ex vivo [<a href="#rid79">79</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In mouse models of allergen-induced pulmonary disease, exogenous administration of LTE<sub>4</sub> markedly increases the numbers of mucus-producing goblet cells in the airways [<a href="#rid80">80</a>]. Notably, this response persists even in mice lacking both CysLT<sub>1</sub>R and CysLT<sub>2</sub>R, suggesting the involvement of an additional receptor, such as CysLT<sub>3</sub>R [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The above response to LTE<sub>4</sub> requires both platelets and the platelet-associated adenosine diphosphate receptor (P<sub>2</sub>Y<sub>12</sub>) [<a href="#rid80">80</a>]. Because LTE<sub>4</sub> neither binds P<sub>2</sub>Y<sub>12</sub> nor activates platelets, these findings argue for an indirect, downstream role of platelets.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intranasal administration of LTE<sub>4</sub> to immunologically naïve mice causes the release of mucins from nasal goblet cells [<a href="#rid46">46</a>]. This response is abolished in mice lacking<sub> </sub>CysLT<sub>3</sub>R, suggesting that at least some of the direct stimulatory effects of the CysLTs on mucus production may be due to this receptor [<a href="#rid80">80</a>].</p><p></p><p class="headingAnchor" id="H1758320246"><span class="h3">Mast cell activation</span><span class="headingEndMark"> — </span>Mast cell activation by LTE<sub>4</sub> is largely mediated through CysLT<sub>1</sub>R, although interactions between CysLT<sub>1</sub>R and CysLT<sub>2</sub>R on mast cells may modulate the response to LTE<sub>4</sub>.</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary levels of a prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) metabolite, a marker of mast cell activation, increase sharply in response to inhalation of LTE<sub>4</sub> by human asthmatic subjects [<a href="#rid39">39</a>]. Both the increase in PGD<sub>2</sub> and the reduction in FEV<sub>1</sub> elicited by LTE<sub>4</sub> challenge are blocked by the administration of the selective CysLT<sub>1</sub>R antagonist <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>. Stimulation of human cord blood-derived mast cells with CysLTs ex vivo results in strong calcium flux, production of cytokines and chemokines, and production of PGD<sub>2</sub>, responses that are blocked by CysLT<sub>1</sub>R antagonists [<a href="#rid81">81,82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Like many hematopoietic cells, mast cells express both CysLT<sub>1</sub>R and CysLT<sub>2</sub>R. CysLT<sub>2</sub>R heterodimerizes with CysLT<sub>1</sub>R on the surfaces of mast cells, restricting signaling and surface expression of the latter receptor [<a href="#rid83">83</a>]. Thus, CysLT-induced mast cell activation in vivo may be controlled by a balance of CysLT<sub>1</sub>R and CysLT<sub>2</sub>R expression. Notably, CysLT<sub>1</sub>R expression, but not CysLT<sub>2</sub>R expression, is upregulated in nasal and bronchial tissue mast cells in subjects with AERD [<a href="#rid75">75,76</a>], suggesting a potential mechanism involved in the enhanced reactivity of these subjects to LTE<sub>4</sub>. Whether this reactivity depends on secondary production of bronchoconstricting agonists (such as PGD<sub>2</sub>) by mast cells is not known.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proliferation of mast cells in epithelial surfaces is a feature of Th2-associated allergic disease. CysLTs contribute to modest proliferation of human and mouse mast cells ex vivo through CysLT<sub>1</sub>R-dependent transactivation of the Kit tyrosine kinase [<a href="#rid84">84</a>].</p><p></p><p class="headingAnchor" id="H3605674103"><span class="h3">Dendritic cell priming</span><span class="headingEndMark"> — </span>Dendritic cells are antigen-presenting hematopoietic cells that are important in priming T lymphocytes for the development of Th2 memory responses. They reside in close proximity to the respiratory mucosa, capturing antigens for presentation to T cells in the regional lymph nodes [<a href="#rid85">85</a>]. Dendritic cells express all components of the CysLT synthetic pathway [<a href="#rid21">21</a>], as well as both CysLT<sub>1</sub>R and CysLT<sub>2</sub>R [<a href="#rid86">86,87</a>].</p><p>When stimulated with the clinically relevant allergens from the house dust mites <em>Dermatophagoides farinae</em> and <em>Dermatophagoides pteronyssinus</em> or the mold <em>Aspergillus fumigatus</em>, dendritic cells generate substantial quantities of CysLTs [<a href="#rid20">20</a>] and acquire the ability to prime naïve mouse T lymphocytes for subsequent generation of Th2 memory responses [<a href="#rid87">87</a>]. Notably, dendritic cells lacking either LTC<sub>4</sub>S (which are incapable of generating LTC<sub>4</sub>) or CysLT<sub>1</sub>R display markedly blunted capacity to elicit Th2 priming in vivo [<a href="#rid87">87</a>].</p><p>Conversely, dendritic cells lacking CysLT<sub>2</sub>R show enhanced Th2 priming, possibly due to the loss of CysLT<sub>2</sub>R interaction with CysLT<sub>1</sub>R, which can downregulate surface expression and signaling through CysLT<sub>1</sub>R, as is the case for mast cells [<a href="#rid86">86</a>] (see <a class="local">'Mast cell activation'</a> above). Although these findings suggest that agents that block CysLT production or CysLT<sub>1</sub>R signaling could hold promise in the prevention of early life sensitization to common antigens that are associated with asthma, no human studies have addressed this possibility. One small, controlled trial demonstrated reductions in total serum immunoglobulin E (IgE) in asthmatic children treated with the CysLT<sub>1</sub>R antagonist <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H2071930357"><span class="h3">Lymphocyte activation</span><span class="headingEndMark"> — </span>Human Th2 cells express CysLT<sub>1</sub>R to a greater extent than do Th1 cells [<a href="#rid40">40</a>] and respond to LTE<sub>4</sub> by generating IL-5 and IL-13. This response is substantially potentiated by simultaneous stimulation with PGD<sub>2</sub> [<a href="#rid40">40</a>], suggesting that lipids generated by activated mast cells are sufficient to elicit polyclonal activation of Th2 cells.</p><p>CysLTs may potentiate type 2 immune responses to helminths and other stimuli that breach epithelial barriers and activate group 2 innate lymphoid cells (ILC2s). ILC2s are poised effector cells that lack T cell receptors and can generate large quantities of IL-5, IL-13, and other cytokines when activated by epithelial-derived cytokines (eg, IL-25, IL-33, thymic stromal lymphopoietin) [<a href="#rid89">89</a>]. ILC2s express CysLT<sub>1</sub>R and respond to exogenous CysLTs by generating IL-4, IL-5, and IL-13 [<a href="#rid41">41,42,90</a>]. Additionally, CysLTs markedly potentiate the production of cytokines by ILC2s stimulated with IL-25 or IL-33 [<a href="#rid27">27,91</a>]. Additionally, CysLT<sub>1</sub>R antagonists and 5-LO inhibitors may exert part of their therapeutic effects by attenuating cytokine secretion by lymphoid effectors.</p><p class="headingAnchor" id="H2008009768"><span class="h3">Eosinophil and basophil recruitment</span><span class="headingEndMark"> — </span>Experimental inhalation of LTE<sub>4</sub> by subjects with mild to moderate asthma results in sustained increases in eosinophils [<a href="#rid92">92,93</a>] and basophils [<a href="#rid93">93</a>] in induced sputum and bronchial biopsies. This response is attenuated by treatment with CysLT<sub>1</sub>R antagonists [<a href="#rid94">94</a>]. Murine studies suggest that effector cell recruitment involves input from all three CysLT receptors [<a href="#rid47">47,48,93,95,96</a>].</p><p class="headingAnchor" id="H15"><span class="h1">CLINICAL USE OF LEUKOTRIENE-MODIFYING DRUGS IN ASTHMA</span><span class="headingEndMark"> — </span>Antileukotriene agents reduce asthmatic responses to bronchoprovocation challenge, as expected based on the effects of leukotrienes described above. (See <a class="local">'Functions of leukotrienes relevant to asthma pathogenesis'</a> above.).</p><p></p><p>Physiologic findings of airflow obstruction induced by exercise, allergen, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, and the pollutant sulfur dioxide are all substantially attenuated by pretreatment with either cysteinyl leukotriene-1 (CysLT<sub>1</sub>) antagonists or the 5-lipoxygenase (5-LO) inhibitor, <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> [<a href="#rid97">97-101</a>]. In the case of allergen-induced asthmatic reactions, both early- and late-phase bronchoconstrictor responses are attenuated [<a href="#rid102">102</a>]. These agents are also useful in long-term asthma control.</p><p>Approaches to the treatment of asthma in children and adults are provided separately. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/5744.html" rel="external">"Asthma in children younger than 12 years: Management of persistent asthma with controller therapies"</a>.)</p><p class="headingAnchor" id="H2046020118"><span class="h2">Available antileukotriene agents</span><span class="headingEndMark"> — </span>In the United States, three antileukotriene agents (also known as leukotriene modifying agents) are available for the treatment of asthma  (<a class="graphic graphic_table graphicRef77367" href="/z/d/graphic/77367.html" rel="external">table 1</a>). Availability in other countries varies, as specified below. Safety in pregnancy and lactation are discussed below. (See <a class="local">'Safety in pregnancy and breastfeeding'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">Montelukast</a> and <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a> are cysteinyl leukotriene (CysLT<sub>1</sub>) receptor antagonists. Pranlukast, available in Japan, is another CysLT<sub>1</sub> receptor antagonist. In most of Europe, only montelukast is available. Montelukast is administered once daily, and zafirlukast and pranlukast are administered twice daily; the usual doses are provided in the table  (<a class="graphic graphic_table graphicRef77367" href="/z/d/graphic/77367.html" rel="external">table 1</a>). Montelukast is approved for use in children older than one year, while zafirlukast is approved for children older than five years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">Zileuton</a> is an inhibitor of 5-LO and thus acts “further upstream” and inhibits the formation of both the CysLTs (and, hence, attenuates stimulation of all three CysLT receptors) and other 5-LO metabolites including LTB<sub>4</sub>  (<a class="graphic graphic_figure graphicRef75064" href="/z/d/graphic/75064.html" rel="external">figure 1</a>). This agent is only available in the United States and is approved for use in children 12 years and older. Zileuton is available in two preparations: immediate release (600 mg, four times daily) and controlled release (1200 mg, twice daily)  (<a class="graphic graphic_table graphicRef77367" href="/z/d/graphic/77367.html" rel="external">table 1</a>) [<a href="#rid103">103</a>]. Regular monitoring of serum alanine aminotransferase is recommended, as described below. (See <a class="local">'Adverse effects'</a> below.)</p><p></p><p class="headingAnchor" id="H1040549293"><span class="h2">Comparisons among antileukotriene agents</span><span class="headingEndMark"> — </span>Comparisons among antileukotriene agents are limited, but include the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">Montelukast</a><strong> versus </strong><a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a> – There are no efficacy data favoring either one of the CysLT<sub>1</sub> antagonists available in the United States (montelukast and zafirlukast) over the other  (<a class="graphic graphic_table graphicRef77367" href="/z/d/graphic/77367.html" rel="external">table 1</a>). However, montelukast is commonly preferred because it is once daily and can be taken at any time in relation to meals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">Zileuton</a><strong> versus </strong><a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> – In a head-to-head comparison, 210 patients with mild to moderate asthma on no other medications were assigned to take the 5-LO inhibitor, zileuton or montelukast, for 12 weeks [<a href="#rid104">104</a>]. Zileuton demonstrated slightly greater efficacy than montelukast in improving peak flow (64.8 L/min [95% CI 54.8-74.7] versus 40.6 L/min [95% CI 31.3-49.9], respectively) and symptom scores, with comparable tolerability. This study supports the theoretical advantage of zileuton over the receptor antagonists since it inhibits production of all the CysLTs and other 5-LO metabolites including LTB<sub>4</sub>, although the magnitude of the difference appears to be small  (<a class="graphic graphic_figure graphicRef75064" href="/z/d/graphic/75064.html" rel="external">figure 1</a>). (See <a class="local">'Leukotriene biology'</a> above.)</p><p></p><p class="bulletIndent1">We are aware of a number of anecdotal experiences with patients who clinically benefited from <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> after failing CysLT<sub>1</sub> antagonist therapy, particularly those with aspirin-exacerbated respiratory disease (AERD). Post-hoc analysis of data from clinical trials suggests that zileuton has a greater impact in patients with more severe rather than milder airflow obstruction, although conflicting data also exist [<a href="#rid105">105,106</a>]. (See <a class="local">'Special populations'</a> below.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Use as initial controller therapy</span><span class="headingEndMark"> — </span>Initial controller therapies for asthma include two groups of medications: inhaled glucocorticoids (inhaled GCs) and antileukotriene agents [<a href="#rid107">107,108</a>]. Both have beneficial effects on clinical symptoms and lead to decreases in markers of inflammation, although these properties have been best characterized for inhaled GCs. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management", section on 'Mild persistent'</a> and  <a class="medical medical_review" href="/z/d/html/5744.html" rel="external">"Asthma in children younger than 12 years: Management of persistent asthma with controller therapies", section on 'Daily LTRA'</a>.)</p><p class="headingAnchor" id="H3569125391"><span class="h3">Predicting response</span><span class="headingEndMark"> — </span>Individuals differ in their response to antileukotriene agents. Some patients respond dramatically, but others show no response at all. Symptom-based outcomes appear to be favorably affected in 60 to 80 percent of patients, whereas improvements in lung function are noted in a lower proportion of subjects (35 to 50 percent) [<a href="#rid109">109,110</a>].</p><p class="headingAnchor" id="H47109011"><span class="h3">Therapeutic trial</span><span class="headingEndMark"> — </span>A therapeutic trial is necessary to assess the utility of an antileukotriene agent in any individual patient, since it is impossible to reliably predict responsiveness. It is our practice to employ a one to two month trial, regardless of which agent is selected and whether the leukotriene modifier is being utilized as first-line or add-on therapy. Both objective and subjective parameters must be assessed in order to comprehensively gauge benefit [<a href="#rid111">111,112</a>].</p><p>It is possible to see benefit as early as the first day of treatment with antileukotriene agents in both adults and children [<a href="#rid34">34,113,114</a>]. This likely reflects the intrinsic bronchodilator activity of antileukotrienes, and the fact that leukotriene overproduction at baseline contributes to increased bronchial tone. An anti-inflammatory effect, as judged by reductions in exhaled nitric oxide and bronchial hyperresponsiveness, has been observed within one and two weeks of initiation of therapy, respectively [<a href="#rid115">115,116</a>]. Improvements in lung function and symptoms may occur more gradually over several weeks to months [<a href="#rid112">112,117</a>].</p><p>The kinetics of improvement for different endpoints within individual patients have not been studied.</p><p class="headingAnchor" id="H3084241999"><span class="h3">Relative efficacy</span></p><p class="headingAnchor" id="H17"><span class="h4">Compared with placebo</span><span class="headingEndMark"> — </span>Antileukotriene agents can be effective as monotherapy in the treatment of mild-to-moderate persistent asthma. Both <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> and CysLT<sub>1</sub>R antagonists elicit rapid and sustained effects on measures of airflow  (<a class="graphic graphic_figure graphicRef54679" href="/z/d/graphic/54679.html" rel="external">figure 3</a>). Each agent has been shown in randomized trials to be superior to placebo in the following outcome measures [<a href="#rid97">97,103,113,118-121</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Lung function (typically resulting in a 10 to 15 percent improvement in forced expiratory volume in one second [FEV<sub>1</sub>] and improvement in measures of distal lung function, with a &gt;10 percent improvement generally being considered to be a minimally important difference)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Daytime and nighttime asthma symptoms and asthma-specific quality of life</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for rescue beta-agonist therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frequency of asthma exacerbations</p><p></p><p>Monotherapy with leukotriene receptor antagonists was evaluated in a 2015 systematic review and meta-analysis of studies involving adults and adolescents with mild asthma and reduced the risk of exacerbation (risk ratio [RR] 0.60, 95% CI 0.44-0.81) [<a href="#rid120">120</a>]. However, the review noted a high risk of bias in some studies, in addition to heterogeneity in results and an inability to assess the effect of asthma severity on the results.</p><p><a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">Montelukast</a> and <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a> are also effective in children. Specifically, children with moderate persistent asthma who were treated with montelukast experienced improved lung function at baseline, decreased asthma symptoms, increased asthma-specific quality of life, and decreased need for asthma rescue medication use, compared with placebo [<a href="#rid34">34,122,123</a>].</p><p>A randomized trial of <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> monotherapy in adults with mild-to-moderate asthma demonstrated an increase in FEV<sub>1</sub> of 0.32 L (CI 0.16-0.48 L), a 13 percent increase, compared with a 0.05 L (CI -0.10 to 0.20 L) increase in patients given placebo [<a href="#rid97">97</a>]. Another trial found that after 12 weeks of therapy, FEV<sub>1</sub> improved by a mean of 0.39 L (20 percent) and 0.27 L (13 percent) with zileuton and placebo, respectively [<a href="#rid103">103</a>]. Symptoms and frequency of beta-agonist use also decreased with zileuton [<a href="#rid97">97,103</a>].</p><p>No evidence of tolerance to these beneficial effects has been noted during treatment for periods up to two years.</p><p class="headingAnchor" id="H18"><span class="h4">Compared with inhaled glucocorticoids</span><span class="headingEndMark"> — </span>Leukotriene modifiers exert anti-inflammatory effects, such as reducing the numbers of circulating and sputum eosinophils, exhaled nitric oxide, and nonspecific bronchial hyperresponsiveness, in addition to their bronchodilatory actions [<a href="#rid115">115,124,125</a>]. In general, however, the magnitude of such anti-inflammatory effects is less than those of inhaled GCs [<a href="#rid126">126</a>].</p><p>In clinical trials comparing these two classes of controller agents, inhaled GCs are usually superior [<a href="#rid126">126</a>]. However, the nature and magnitude of the differences between these treatments are variable. In some of these trials, inhaled GCs were superior in all endpoints examined, while in others, they were superior only in some outcomes [<a href="#rid111">111,127,128</a>]. Specifically, inhaled GCs, when compared with leukotriene modifiers, tend to improve lung function measures more than inflammation or patient-centered outcomes (symptoms, quality of life, or resource utilization) [<a href="#rid112">112,126,129</a>]. A few studies have found no significant differences between the two drug classes [<a href="#rid130">130-133</a>]. Comparative studies typically utilize mean group data to compare the two active agents, a practice which obscures interpatient variation and limits extrapolation to clinical practice. (See <a class="local">'Comparisons among antileukotriene agents'</a> above.)</p><p class="headingAnchor" id="H19"><span class="h3">"Real-world" benefits</span><span class="headingEndMark"> — </span>While efficacy comparisons assessing physiologic outcomes generally favor inhaled GCs over antileukotriene agents, "real-world" effectiveness also depends upon other factors, especially compliance [<a href="#rid133">133</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>It is well known that patient adherence to inhaled GC is suboptimal, and most studies have demonstrated superior patient adherence to once-daily <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> than to inhaled GC in both children and adults [<a href="#rid131">131,132,134,135</a>]. The superior adherence to montelukast may explain its comparable beneficial effects on asthma control to those of inhaled GC in some "real-world" studies [<a href="#rid135">135,136</a>]. Despite the importance of this issue in clinical practice, it is largely circumvented in clinical trials by having study coordinators provide frequent reminders to patients and by excluding those patients whose adherence (as documented by electronic monitors built into the inhaler devices) is deemed insufficient. (See  <a class="medical medical_review" href="/z/d/html/556.html" rel="external">"Enhancing patient adherence to asthma therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is also apparent that primary care clinicians tend to under-prescribe inhaled GCs.</p><p></p><p>Thus, no matter how efficacious inhaled GC may be, their utility in real-world settings is limited by suboptimal dosing, inhaler technique, and adherence. While not the preferred choice based upon efficacy in study populations, antileukotrienes may be considered a reasonable first-line controller agent for patients who either will not take or cannot tolerate inhaled GC. Validation of this approach is supported by a so-called "pragmatic" trial conducted in 306 patients managed in primary care practices, in which <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> was demonstrated to be comparable to inhaled GC as a first-line controller therapy [<a href="#rid133">133</a>].</p><p class="headingAnchor" id="H1040865479"><span class="h2">Use as add-on controller therapy</span><span class="headingEndMark"> — </span>Antileukotriene agents may provide a modest degree of additive benefit for some patients with moderate or severe persistent asthma whose disease is inadequately controlled with inhaled GCs [<a href="#rid107">107,108,137</a>], although addition of a long-acting beta agonist to inhaled GC generally results in superior asthma control and fewer exacerbations compared with addition of an antileukotriene. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Antileukotriene agents'</a> and  <a class="medical medical_review" href="/z/d/html/5744.html" rel="external">"Asthma in children younger than 12 years: Management of persistent asthma with controller therapies", section on 'Inhaled glucocorticoid plus LTRA'</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Additive benefit to inhaled GC</span><span class="headingEndMark"> — </span>Antileukotriene agents may provide modest additive benefit when used as adjunctive therapy with inhaled GC, although differences among patients in response to combined therapy have not been studied [<a href="#rid138">138,139</a>].</p><p>Several studies support the conclusion that glucocorticoids have minimal effects on leukotriene biosynthesis or responses, and persistent overproduction of leukotrienes has been repeatedly documented in patients on substantial doses of inhaled GC [<a href="#rid140">140-145</a>]. A combination of the two types of medications, therefore, may afford complementary anti-inflammatory and bronchoprotective actions.</p><p>Two clinical questions have been addressed regarding the additivity between inhaled GCs and antileukotriene agents:</p><p class="bulletIndent1"><span class="glyph">●</span>Does addition of an antileukotriene improve asthma control in a patient whose control is inadequate on inhaled GC alone? This question has been addressed in both adults and children with variable results [<a href="#rid120">120,138,146-151</a>]. A systematic review and meta-analysis (four studies, 815 participants) found that the number of exacerbations was reduced (RR 0.50, 95% CI 0.29-0.86) with addition of an antileukotriene agent [<a href="#rid152">152</a>].</p><p></p><p class="bulletIndent1">When comparing the addition of an antileukotriene agent to inhaled GC with increasing the dose of the inhaled GC, a systematic review and meta-analysis (eight studies, 2008 participants) found no difference in lung function tests or in the number of participants with exacerbations requiring oral glucocorticoids [<a href="#rid152">152</a>].</p><p></p><p class="bulletIndent1">Some studies note that subjective measures or indices of inflammation are more sensitive to the beneficial effects of add-on leukotriene modifier than are lung function measurements [<a href="#rid129">129,142</a>]. A possible explanation is that the intrinsic bronchodilatory actions of antileukotriene drugs may be difficult to discern when patients' lung function has already improved from inhaled GC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does addition of an antileukotriene, in a patient with controlled asthma, allow control to be maintained despite reducing the dose of inhaled GC (ie, a steroid-sparing effect)? A systematic review and meta-analysis (seven studies, 1150 adults and adolescents) found that adding an antileukotriene agent did not significantly improve the likelihood of success in tapering the inhaled GC dose [<a href="#rid152">152</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h3">Compared with long-acting beta-agonists</span><span class="headingEndMark"> — </span>For patients who remain symptomatic despite inhaled GC therapy, treatment guidelines recommend the addition of a second agent from a different therapeutic class [<a href="#rid107">107,108,153</a>]. Several randomized trials have compared <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> with LABAs in this setting. Predictably, reduction in blood markers of inflammation (eg, eosinophilia) favored montelukast over <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>, while improvements in lung function favored salmeterol [<a href="#rid117">117,154-157</a>]. A systematic review and meta-analysis (eight studies, 5923 adults and 334 children) found that addition of a LABA tends to provide superior asthma control and a reduced risk of exacerbation compared with the addition of a leukotriene receptor antagonist (risk ratio 0.87, 95% CI 0.76-0.99) [<a href="#rid158">158</a>].</p><p>However, not all studies comparing the effects of adding antileukotriene agents or LABAs to inhaled GC therapy have concluded that LABAs are better. Comparable benefit was seen in some, particularly in the outcome of reduced rates of exacerbation, suggesting that both are useful in this regard [<a href="#rid117">117,133,154</a>]. As noted above, in a "pragmatic" trial in primary care practices, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> was found to be comparable to a LABA as add-on therapy for patients inadequately controlled on inhaled GC alone [<a href="#rid133">133</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Special populations</span><span class="headingEndMark"> — </span>Individuals differ in their responses to antileukotriene agents [<a href="#rid111">111,112</a>]. Certain clinical characteristics are associated with greater responsiveness, although substantial variability characterizes responses within each of these patient populations.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspirin-exacerbated respiratory disease (AERD)</strong> – Subjects with AERD are consistently overrepresented in population studies of severe asthma [<a href="#rid159">159,160</a>] and also tend to have severe, recalcitrant nasal polyposis [<a href="#rid161">161</a>]. In addition to displaying selective hyperresponsiveness to exogenous inhaled LTE<sub>4</sub> [<a href="#rid73">73,74</a>], these individuals also exhibit markedly dysregulated 5-LO pathway activity and CysLT overproduction (as evidenced by urinary LTE<sub>4</sub> levels that exceed those observed in aspirin-tolerant asthmatic controls) [<a href="#rid32">32,162</a>]. Compared with placebo, both <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> and CysLT<sub>1</sub>R antagonists improve baseline symptomatic control and olfaction in patients with AERD [<a href="#rid109">109,163</a>].</p><p></p><p class="bulletIndent1">Oral challenges to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> are commonly used in clinical practice to elicit reactions that establish the diagnosis and to induce desensitization [<a href="#rid77">77</a>]. These reactions produce changes in lung function, as well as sinonasal, ocular, and (occasionally) gastrointestinal and cutaneous symptoms, accompanied by dramatic increases in urinary LTE<sub>4</sub> [<a href="#rid32">32,162</a>]. Prophylaxis with <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> markedly attenuates all features of these reactions [<a href="#rid164">164-166</a>]. Similarly, the administration of CysLT<sub>1</sub>R antagonists prior to the challenge can attenuate the decline in FEV<sub>1</sub>, increasing the safety margin of the challenge [<a href="#rid167">167</a>]. These findings collectively validate the pathogenetic role of the CysLTs in AERD. Prophylaxis with either zileuton or with CysLT<sub>1</sub>R antagonists is commonly used to improve the safety of therapeutic desensitization procedures in AERD. (See  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a> and  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Premedication for oral protocols'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise-induced symptoms</strong> – Antileukotriene agents are generally highly protective against exercise-induced bronchospasm (EIB). <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">Montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>, and <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> all ameliorate EIB to a similar degree [<a href="#rid168">168</a>]. Montelukast can be particularly useful in young children with EIB, who exert themselves unpredictably throughout the day.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">Montelukast</a> and <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> have been compared with respect to their capacity to inhibit EIB [<a href="#rid169">169,170</a>]. On the third day of treatment, the agents had similar effects, but after four and eight weeks the effects of montelukast were sustained while those of salmeterol had waned. The combination of montelukast plus salmeterol was shown in one study to provide greater protection against EIB than either agent alone [<a href="#rid171">171</a>].</p><p></p><p class="bulletIndent1">Protection against EIB with <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> is detectable as early as two hours after a single oral dose and persists for up to 24 hours [<a href="#rid172">172</a>]. For patients who require specific pretreatment prior to exercise, regardless of whether they are on chronic controller therapy, a leukotriene modifier dosed two hours prior to exercise is a reasonable and effective alternative to pretreatment with short-acting beta-agonists and is US Food and Drug Administration approved for this indication. (See  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral upper respiratory infection (URI)-induced</strong> <strong>symptoms </strong>– There is abundant evidence that leukotrienes are generated during various viral respiratory infections, and <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> reduces the frequency of infection-associated asthma exacerbations in children and ameliorates the symptoms of respiratory syncytial virus-associated exacerbations [<a href="#rid122">122,173</a>]. However, a meta-analysis found that its utility in children without chronic asthma but with episodic viral wheeze is variable and not significant overall [<a href="#rid174">174</a>].</p><p></p><p>Several other patient characteristics have been proposed, although their ability to predict a response to antileukotriene agents has not been convincingly demonstrated.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – On average, children may be more likely than adults to benefit from leukotriene modifier therapy [<a href="#rid110">110</a>]. In a study of mild-to-moderate persistent asthma, younger children were more likely to benefit compared with older children [<a href="#rid175">175</a>]. Whether this might reflect a greater prevalence of symptoms triggered by viral URIs in young children or the tendency of children to be physically active throughout the day remains to be determined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Females</strong> – Consistent with the greater magnitude of leukotriene synthesis in females than males [<a href="#rid49">49,176</a>], sexual dimorphism in treatment responses was evaluated in a large registry-based retrospective study of adult and pediatric patients administered <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> [<a href="#rid177">177</a>]. In adults, males were more likely than females to discontinue montelukast, switch to another therapy, or require rescue therapy with oral GCs or short-acting beta-agonists. By contrast, no sex-related differences were observed in pediatric patients. Conclusions about possible variation in antileukotriene responses by sex must await prospective studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms triggered by air pollutants</strong> – Leukotrienes are produced upon respiratory tract exposure to pollutants, such as sulfur dioxide and particulates. CysLT<sub>1</sub> receptor antagonists reduce airway inflammation and bronchoconstrictor responses to both types of pollutants in laboratory challenge settings [<a href="#rid101">101,178,179</a>]. However, the specific utility of antileukotrienes in ameliorating or preventing pollutant-induced asthma has not been explored.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asthma severity</strong> – Guideline-based management does not advocate using antileukotriene agents as monotherapy in moderate or severe persistent asthma, although it can be given as an adjunct therapy. (See  <a class="medical medical_review" href="/z/d/html/532.html" rel="external">"Ongoing monitoring and titration of asthma therapies in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Antileukotriene agents'</a>.)</p><p></p><p class="bulletIndent1">In our experience, severity alone is not particularly helpful in predicting the likelihood of a response to a leukotriene modifier versus an inhaled GC. This was supported by a retrospective study that found that although <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> was more often prescribed to patients with severe asthma, asthma severity did not predict responsiveness [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic rhinitis</strong> – As allergic rhinitis coexists with asthma in many patients and randomized trials indicate that antileukotrienes have modest efficacy in allergic rhinitis, antileukotrienes may ameliorate both upper and lower airway disease. In a retrospective, observational study of several thousand patients with both conditions, approximately 80 percent of patients reported meaningful improvement in both conditions with <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> treatment [<a href="#rid180">180</a>]. In a large open-label study of montelukast addition to either inhaled GC or inhaled GC plus LABA in adult asthmatics with inadequately controlled mild to moderate asthma, subjects with coexisting allergic rhinitis had numerically superior asthma control scores than did those without allergic rhinitis [<a href="#rid181">181</a>].</p><p></p><p class="bulletIndent1">However, it has<strong> not</strong> been our experience that patients with both conditions or patients with atopic triggers for their asthma are any more likely to benefit from leukotriene modifiers than are patients without concomitant allergic rhinitis or atopy. In addition, a boxed warning was placed on <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> advising against its use for allergic rhinitis or mild asthma. (See <a class="local">'Adverse effects'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity</strong> – Obesity is associated with an increased relative risk and severity of asthma and reduced efficacy of asthma medications. While some studies suggest a benefit of leukotriene modifiers in maintaining asthma control, most studies have found that inhaled GC is superior to <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> in all body mass index categories. For patients with obesity and suboptimally controlled asthma on an inhaled GC, addition of a long-acting bronchodilator (LABA) appears more effective than addition of an antileukotriene agent. (See  <a class="medical medical_review" href="/z/d/html/119911.html" rel="external">"Obesity and asthma", section on 'Pharmacologic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cigarette smoking</strong> – Cigarette smoking stimulates CysLT production; urinary LTE<sub>4</sub> is increased in a dose-dependent fashion in smokers [<a href="#rid182">182</a>]. However, antileukotriene agents do not appear to have particular efficacy in patients with asthma who smoke. In a trial of over 1000 currently smoking patients with asthma randomized to treatment with either inhaled <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a>, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, or placebo for six months, both active treatments were superior to placebo (and no different from each other) in improving asthma control [<a href="#rid183">183</a>].</p><p></p><p class="headingAnchor" id="H1159113102"><span class="h2">Safety in pregnancy and breastfeeding</span></p><p class="bulletIndent1"><span class="glyph">●</span>Data regarding use of the cysteinyl leukotriene (CysLT<sub>1</sub>) receptor antagonists (<a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>, and pranlukast) during pregnancy are reassuring, but limited. These drugs are passed to the breast milk but in very small amounts that are generally considered safe for infants [<a href="#rid184">184</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> is generally avoided during pregnancy because adverse effects were noted in animal reproduction studies. Passage to breast milk has not been studied.</p><p></p><p>Specific studies of use in antileukotriene medications in pregnancy are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/554.html" rel="external">"Management of asthma during pregnancy", section on 'Leukotriene modifiers'</a>.)</p><p class="headingAnchor" id="H2817755167"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>The leukotriene receptor antagonists, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>, and pranlukast, are generally well-tolerated. <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">Zileuton</a> is associated with more frequent adverse effects, including liver inflammation and drug interactions.</p><p class="headingAnchor" id="H2453897588"><span class="h2">Leukotriene receptor antagonists</span><span class="headingEndMark"> — </span>Adverse effects have been described in small numbers (≤2 percent) of individuals receiving <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a> or <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, including anaphylaxis, angioedema, dizziness, dyspepsia, muscle weakness, and elevated transaminases.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Boxed warning about </strong><a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a><strong> and neuropsychiatric adverse effects </strong>– The US Food and Drug Administration (FDA) has placed a boxed warning on montelukast, advising that all patients should be warned about potential behavior and mood-related changes; providers should consider the potential risks and benefits of montelukast, particularly when the patient has mild asthma or allergic rhinitis or a history of psychiatric illness; and patients should be monitored for neuropsychiatric symptoms when taking montelukast [<a href="#rid185">185</a>]. This warning is based on postmarketing surveillance of neuropsychiatric events (eg, agitation, depression, insomnia, suicidal thoughts and actions) among patients taking montelukast. It should be noted that depression and suicidality are more common in patients with asthma than in the general population [<a href="#rid186">186</a>].</p><p></p><p class="bulletIndent1">Published data regarding potential neuropsychiatric effects are mixed [<a href="#rid187">187-193</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A scientific review of clinical trial data requested by the FDA did <strong>not</strong> find an increase in suicidal ideation in subjects taking <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> compared with those on placebo [<a href="#rid187">187</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A systematic review concluded that the evidence for and against an effect was of low quality and relied on pharmacovigilance more than randomized trials or high-quality observational data [<a href="#rid191">191</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subsequent observational studies suggest a small increased risk of neuropsychiatric events associated with <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> prescription. An 11-year study of children aged 5 to 18 years in Ontario, Canada, found that the 898 children experiencing new-onset neuropsychiatric events (eg, anxiety, sleep disturbance) were almost twice as likely as the 3497 controls to have been prescribed montelukast in the year before the event (OR 1.91) [<a href="#rid190">190</a>]. A health records database study of 72,490 adolescents and adults with asthma found that those exposed to montelukast had a small increase in insomnia (19 versus 16 cases per 1000, OR 1.13) anxiety disorders (64 versus 57 cases per 1000, OR 1.21), and new antidepressant use (59 versus 52 per 1000, OR 1.16) in the first year after montelukast treatment compared with matched montelukast-unexposed patients [<a href="#rid192">192</a>]. A Danish national registry study of adults showed similar overall results, but the effect was only evident in younger patients (new neuropsychiatric medication use after montelukast exposure compared with unexposed patients: OR 1.38 in adults aged 18 to 29 years, OR 1.17 in adults aged 30 to 44 years, and OR 0.95-1.0 in adults aged &gt;45 years) [<a href="#rid194">194</a>].</p><p></p><p class="headingAnchor" id="H3710428111"><span class="h2">Zileuton</span><span class="headingEndMark"> — </span>Side effects associated with <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> include headache (23 to 25 percent), dyspepsia (8 percent), myalgias (7 percent), leukopenia (1 to 3 percent), elevated transaminases (2 to 5 percent), sleep disorders (&lt;1 percent), and behavior changes (&lt;1 percent) [<a href="#rid195">195</a>]. Use in patients with a history of liver disease or substantial alcohol consumption should be avoided. The manufacturer recommends monitoring serum alanine aminotransferase (ALT) monthly for the first three months, every two to three months for the rest of the first year, and periodically thereafter. Zileuton should be discontinued if ALT is ≥3 times normal, which occurred in 2 percent of patients treated with zileuton for at least one year, compared with 0.2 percent of placebo recipients [<a href="#rid196">196</a>]. These elevations were usually transient, asymptomatic, and rapidly reversible, and most often appeared within four to eight weeks of starting therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug interactions are possible; <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> inhibits cytochrome CYP1A2 and has a mild interaction with CYP1A2, 2C9, 3A4. For this reason, <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> dosing may have to be adjusted downwards.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss)-like syndrome develops as a rare complication in steroid-dependent asthmatics treated with antileukotriene agents, typically the leukotriene receptor antagonists [<a href="#rid197">197</a>]. In most instances, this occurs following tapering of the oral glucocorticoid dose, suggesting that underlying EGPA may be unmasked by glucocorticoid withdrawal, rather than being caused by the drugs themselves. However, at least one analysis argues against dismissing a possible causal relationship [<a href="#rid198">198</a>]. The pathogenesis of EGPA is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Leukotriene modifying agents'</a>.)</p><p></p><p class="headingAnchor" id="H3725769529"><span class="h1">FUTURE DIRECTIONS</span><span class="headingEndMark"> — </span>Areas of ongoing investigation include the use of biomarkers and genotypic markers to predict which patients are most likely to respond to antileukotriene agents and a possible role for antileukotriene agents in acute asthma. In addition, the potential therapeutic value of antagonists to leukotriene receptors other than cysteinyl leukotriene-1 (CysLT<sub>1</sub>), of inhibitors of biosynthetic enzymes other than 5-lipoxygenase, and of combinations of antileukotriene drugs with different mechanisms of action all require further research.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biomarkers</strong> – Biomarkers that reflect leukotriene production are an active area of investigation, although these markers are not currently used in clinical practice [<a href="#rid59">59,109,199,200</a>]. One obvious candidate biomarker is the degree of leukotriene overproduction itself. One study found that mean levels of ex vivo CysLT production by stimulated whole blood leukocytes were higher in patients deemed to be responders to a CysLT1 antagonist than in nonresponders, but the sensitivity and specificity of this parameter were inadequate to guide clinical decision-making [<a href="#rid199">199</a>].</p><p></p><p class="bulletIndent1">Studies examining urinary leukotriene E4 (LTE<sub>4</sub>) levels as a predictor of response to antileukotriene drugs have yielded variable results. For example, some studies in patients with moderate persistent asthma or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> intolerant asthma have shown no relationship [<a href="#rid109">109,200</a>]. An inverse relationship was reported between urinary LTE<sub>4</sub> and response to a CysLT<sub>1</sub>R antagonist in another study [<a href="#rid201">201</a>]. In the largest series reported (albeit still only comprising 48 patients), a correlation among mild-moderate asthmatics between urinary LTE<sub>4</sub> and responsiveness was observed, but again the sensitivity and specificity were inadequate to be clinically useful [<a href="#rid202">202</a>]. (See  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotypic markers</strong> – Polymorphisms in genes encoding 5-lipoxygenase (5-LO) and LTC<sub>4</sub>S may predict responsiveness to antileukotriene drugs. However, it is not clear whether the possible predictive value of these variant genotypes is actually explained by altered leukotriene synthetic capacity because of uncertainty regarding the relationship between the degree of leukotriene overproduction and response to leukotriene modifiers, as well as the precise impact of these variant genotypes on leukotriene synthetic capacity.</p><p></p><p class="bulletIndent1">Variants of the 5-LO promoter are associated with diminished responses to a 5-LO inhibitor [<a href="#rid203">203</a>]. However, these variants occur in fewer than 10 percent of asthmatics and therefore cannot explain much of the observed nonresponsiveness to leukotriene modifiers.</p><p></p><p class="bulletIndent1">A polymorphism in the LTC<sub>4</sub> synthase gene is more common, occurring in approximately 20 to 40 percent of asthmatics. A positive relationship between this variant allele and clinical response to antileukotriene drugs has been reported in two studies, although not in a third [<a href="#rid54">54,200,204</a>].</p><p></p><p class="bulletIndent1">Minimal data exist on the possible role of variant leukotriene receptors as determinants of responsiveness to these drugs; one study found that variants in the CysLT<sub>2</sub>R gene were associated with greater responsiveness to a CysLT<sub>1</sub>R antagonist [<a href="#rid205">205</a>]. This puzzling observation can perhaps be explained by in vitro studies demonstrating that CysLT<sub>2</sub>R can interact with and attenuate responses to CysLT<sub>1</sub>R ligation [<a href="#rid83">83</a>]. (See <a class="local">'Mast cell activation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacogenomics</strong> – Variation in drug absorption may contribute to the variability of response to leukotriene modifiers. Genetic variation in the transporter gene <em>SLCO2B1</em> (Solute Carrier Organic Anion Transporter family, member 2B1, MIM 604988) has been associated with variation in <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> plasma levels and with variability of response to montelukast among patients with asthma [<a href="#rid206">206</a>]. The first study to utilize genome-wide association, rather than candidate gene analysis, to interrogate the pharmacogenomics of responses to antileukotriene drugs identified previously unreported loci in genes involved in processing transfer RNA and in glycosylation that were associated with differential responsiveness to leukotriene modifiers [<a href="#rid207">207</a>]. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Drug transport'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher dose </strong><a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> – Anecdotally, some patients describe a benefit from montelukast only when it is used at doses higher than its standard recommended dose of 10 mg daily. Early studies with this drug used at doses up to 600 mg daily showed increases in lung function that were generally greater than those obtained with the 10 mg dose [<a href="#rid208">208</a>]. Since the cytokine-rich milieu of an inflamed asthmatic lung would be expected to increase expression of the CysLT<sub>1</sub>R [<a href="#rid75">75</a>], it is conceivable that higher concentrations of this competitive antagonist might be required for effective receptor blockade, at least in some patients. We agree with the suggestion that montelukast dosing be reconsidered, which would require dedicated clinical trials in various subpopulations [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Novel receptor antagonists</strong> – CysLT<sub>1</sub>R is the only CysLT receptor that has successfully been targeted by US Food and Drug Administration-approved drugs in asthma. A dual CysLT<sub>1</sub>R/CysLT<sub>2</sub>R antagonist showed nearly identical capacity to block allergen-induced early and late phase changes in lung function in allergen-challenged atopic mildly asthmatic subjects [<a href="#rid209">209</a>]. This likely reflects the dominance of CysLT<sub>1</sub>R in mediating CysLT-induced airway smooth muscle responses. Given that both CysLT<sub>2</sub>R [<a href="#rid48">48</a>] and CysLT<sub>3</sub>R [<a href="#rid47">47</a>] contribute prominently to features of eosinophilic inflammation and mucus secretion in preclinical models, it remains plausible that one or both of these receptors will prove to be a fruitful target, particularly in aspirin-exacerbated respiratory disease where both CysLT synthesis and CysLT-associated features of immunopathology are prominent [<a href="#rid210">210</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute treatment of exacerbations</strong> – While not available for clinical use, preliminary studies suggested that addition of an intravenous or high-dose antileukotriene agent to inhaled beta-agonists and systemic glucocorticoids was beneficial in the treatment of asthma exacerbations in the emergency department. The use of antileukotriene agents in this setting is presented separately. (See  <a class="medical medical_review" href="/z/d/html/528.html" rel="external">"Acute exacerbations of asthma in adults: Home and office management"</a>.)</p><p></p><p class="headingAnchor" id="H2235274286"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112325.html" rel="external">"Society guideline links: Asthma in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Leukotrienes are proinflammatory mediators derived from arachidonic acid that contribute to the pathogenesis of asthma. The cysteinyl leukotrienes (CysLTs), LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>, mediate pro-asthmatic effects such as sustained bronchoconstriction, mucus secretion, and airway edema  (<a class="graphic graphic_figure graphicRef75064" href="/z/d/graphic/75064.html" rel="external">figure 1</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Leukotriene biology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antileukotriene agents (also known as leukotriene modifying agents) inhibit the action of leukotrienes by blocking the CysLT<sub>1</sub> receptor (eg, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>, pranlukast) or by interrupting production by 5-lipoxygenase (eg, <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a>)  (<a class="graphic graphic_figure graphicRef75064" href="/z/d/graphic/75064.html" rel="external">figure 1</a>). The usual doses of these agents are provided in the table  (<a class="graphic graphic_table graphicRef77367" href="/z/d/graphic/77367.html" rel="external">table 1</a>). (See <a class="local">'Available antileukotriene agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients respond dramatically to antileukotriene agents, while others show no response at all, and clinical characteristics are poorly predictive of responsiveness in individual patients. To assess the utility of an antileukotriene agent in an individual patient, we typically perform a one to two-month trial, regardless of which agent is selected and whether the leukotriene modifier is being utilized as first-line or add-on therapy. (See <a class="local">'Therapeutic trial'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antileukotriene agents are effective as monotherapy in the treatment of some patients with mild to moderate persistent asthma, although the mean efficacy of antileukotriene agents is lower than that of inhaled glucocorticoids (inhaled GCs). Thus, inhaled GCs are preferred first-line controller agents, and antileukotriene agents are considered alternatives, particularly for patients who have difficulty with adherence or inhaler technique. (See <a class="local">'Relative efficacy'</a> above and  <a class="medical medical_review" href="/z/d/html/527.html" rel="external">"Initiating asthma therapy and monitoring in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/532.html" rel="external">"Ongoing monitoring and titration of asthma therapies in adolescents and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who respond, antileukotriene agents improve lung function and symptom-related quality of life and decrease the frequency of exacerbations and the need for symptom-relieving beta-agonist medications. Thus, they can be useful in patients who cannot tolerate, are unwilling to take, or who have not responded to inhaled GCs. In addition, compliance with oral therapies is generally higher than with inhalers. (See <a class="local">'Use as initial controller therapy'</a> above and <a class="local">'"Real-world" benefits'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with asthma that is inadequately controlled with inhaled GCs, long-acting beta agonists (LABAs) will generally provide superior improvement in lung function compared with antileukotriene agents. However, the advantages of LABAs over antileukotriene agents in other endpoints are more modest. (See <a class="local">'Compared with long-acting beta-agonists'</a> above and <a class="local">'Additive benefit to inhaled GC'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antileukotriene agents are highly protective against exercise-induced bronchoconstriction (EIB), but short-acting beta agonists are usually preferred as they can both prevent and relieve bronchoconstriction. The role of antileukotriene agents in the management of aspirin-exacerbated respiratory disease (AERD) is discussed separately. (See <a class="local">'Special populations'</a> above and  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a> and  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease", section on 'Leukotriene-modifying agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The leukotriene receptor antagonists, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>, and pranlukast (not available in the United States or Canada), are generally well-tolerated. Prescribers and patients should be aware of potential behavioral and neuropsychiatric disturbances with montelukast. <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">Zileuton</a> is associated with more frequent adverse effects, including liver inflammation and drug interactions. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="headingAnchor" id="H3798625465"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Marc Peters-Golden, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Woods JW, Evans JF, Ethier D, et al. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 1993; 178:1935.</a></li><li><a class="nounderline abstract_t">Malaviya R, Malaviya R, Jakschik BA. Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation. J Biol Chem 1993; 268:4939.</a></li><li><a class="nounderline abstract_t">Mancini JA, Evans JF. Cloning and characterization of the human leukotriene A4 hydrolase gene. Eur J Biochem 1995; 231:65.</a></li><li><a class="nounderline abstract_t">Goodarzi K, Goodarzi M, Tager AM, et al. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003; 4:965.</a></li><li><a class="nounderline abstract_t">Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A 1994; 91:7663.</a></li><li><a class="nounderline abstract_t">Samuchiwal SK, Boyce JA. Role of lipid mediators and control of lymphocyte responses in type 2 immunopathology. J Allergy Clin Immunol 2018; 141:1182.</a></li><li><a class="nounderline abstract_t">Evans JF, Dupuis P, Ford-Hutchinson AW. Purification and characterisation of leukotriene A4 hydrolase from rat neutrophils. Biochim Biophys Acta 1985; 840:43.</a></li><li><a class="nounderline abstract_t">Martin TR, Altman LC, Albert RK, Henderson WR. Leukotriene B4 production by the human alveolar macrophage: a potential mechanism for amplifying inflammation in the lung. Am Rev Respir Dis 1984; 129:106.</a></li><li><a class="nounderline abstract_t">Miyahara N, Ohnishi H, Miyahara S, et al. Leukotriene B4 release from mast cells in IgE-mediated airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 2009; 40:672.</a></li><li><a class="nounderline abstract_t">Pal K, Feng X, Steinke JW, et al. Leukotriene A4 Hydrolase Activation and Leukotriene B4 Production by Eosinophils in Severe Asthma. Am J Respir Cell Mol Biol 2019; 60:413.</a></li><li><a class="nounderline abstract_t">Yokomizo T, Izumi T, Chang K, et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387:620.</a></li><li><a class="nounderline abstract_t">Wang S, Gustafson E, Pang L, et al. A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization. J Biol Chem 2000; 275:40686.</a></li><li><a class="nounderline abstract_t">Afonso PV, Janka-Junttila M, Lee YJ, et al. LTB4 is a signal-relay molecule during neutrophil chemotaxis. Dev Cell 2012; 22:1079.</a></li><li><a class="nounderline abstract_t">Tager AM, Bromley SK, Medoff BD, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003; 4:982.</a></li><li><a class="nounderline abstract_t">Miyahara N, Takeda K, Miyahara S, et al. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J Immunol 2005; 174:4979.</a></li><li><a class="nounderline abstract_t">Dakhama A, Collins ML, Ohnishi H, et al. IL-13-producing BLT1-positive CD8 cells are increased in asthma and are associated with airway obstruction. Allergy 2013; 68:666.</a></li><li><a class="nounderline abstract_t">Higham A, Cadden P, Southworth T, et al. Leukotriene B4 levels in sputum from asthma patients. ERJ Open Res 2016; 2.</a></li><li><a class="nounderline abstract_t">Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 2009; 124:406.</a></li><li><a class="nounderline abstract_t">Weller PF, Lee CW, Foster DW, et al. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U S A 1983; 80:7626.</a></li><li><a class="nounderline abstract_t">Barrett NA, Maekawa A, Rahman OM, et al. Dectin-2 recognition of house dust mite triggers cysteinyl leukotriene generation by dendritic cells. J Immunol 2009; 182:1119.</a></li><li><a class="nounderline abstract_t">Machida I, Matsuse H, Kondo Y, et al. Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma. J Immunol 2004; 172:1833.</a></li><li><a class="nounderline abstract_t">Sorgi CA, Zarini S, Martin SA, et al. Dormant 5-lipoxygenase in inflammatory macrophages is triggered by exogenous arachidonic acid. Sci Rep 2017; 7:10981.</a></li><li><a class="nounderline abstract_t">Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012; 119:3790.</a></li><li><a class="nounderline abstract_t">Maugeri N, Evangelista V, Celardo A, et al. Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B2 and leukotriene C4 cooperative synthesis. Thromb Haemost 1994; 72:450.</a></li><li><a class="nounderline abstract_t">Johansson MW, Han ST, Gunderson KA, et al. Platelet activation, P-selectin, and eosinophil β1-integrin activation in asthma. Am J Respir Crit Care Med 2012; 185:498.</a></li><li><a class="nounderline abstract_t">Ualiyeva S, Hallen N, Kanaoka Y, et al. Airway brush cells generate cysteinyl leukotrienes through the ATP sensor P2Y2. Sci Immunol 2020; 5.</a></li><li><a class="nounderline abstract_t">McGinty JW, Ting HA, Billipp TE, et al. Tuft-Cell-Derived Leukotrienes Drive Rapid Anti-helminth Immunity in the Small Intestine but Are Dispensable for Anti-protist Immunity. Immunity 2020; 52:528.</a></li><li><a class="nounderline abstract_t">Shi ZZ, Han B, Habib GM, et al. Disruption of gamma-glutamyl leukotrienase results in disruption of leukotriene D(4) synthesis in vivo and attenuation of the acute inflammatory response. Mol Cell Biol 2001; 21:5389.</a></li><li><a class="nounderline abstract_t">Lee CW, Lewis RA, Corey EJ, Austen KF. Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes. Immunology 1983; 48:27.</a></li><li><a class="nounderline abstract_t">Sala A, Voelkel N, Maclouf J, Murphy RC. Leukotriene E4 elimination and metabolism in normal human subjects. J Biol Chem 1990; 265:21771.</a></li><li><a class="nounderline abstract_t">Taylor GW, Taylor I, Black P, et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1:584.</a></li><li><a class="nounderline abstract_t">Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143:1025.</a></li><li><a class="nounderline abstract_t">Laidlaw TM, Boyce JA. Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy 2012; 42:1313.</a></li><li><a class="nounderline abstract_t">Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:E48.</a></li><li><a class="nounderline abstract_t">Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105:917.</a></li><li><a class="nounderline abstract_t">Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399:789.</a></li><li><a class="nounderline abstract_t">Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001; 163:226.</a></li><li><a class="nounderline abstract_t">Figueroa DJ, Borish L, Baramki D, et al. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy 2003; 33:1380.</a></li><li><a class="nounderline abstract_t">Lazarinis N, Bood J, Gomez C, et al. Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor. J Allergy Clin Immunol 2018; 142:1080.</a></li><li><a class="nounderline abstract_t">Xue L, Barrow A, Fleming VM, et al. Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2. J Immunol 2012; 188:694.</a></li><li><a class="nounderline abstract_t">Xue L, Salimi M, Panse I, et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol 2014; 133:1184.</a></li><li><a class="nounderline abstract_t">Doherty TA, Khorram N, Lund S, et al. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol 2013; 132:205.</a></li><li><a class="nounderline abstract_t">Mellor EA, Maekawa A, Austen KF, Boyce JA. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci U S A 2001; 98:7964.</a></li><li><a class="nounderline abstract_t">Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275:30531.</a></li><li><a class="nounderline abstract_t">Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 2013; 288:10967.</a></li><li><a class="nounderline abstract_t">Bankova LG, Lai J, Yoshimoto E, et al. Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99. Proc Natl Acad Sci U S A 2016; 113:6242.</a></li><li><a class="nounderline abstract_t">Bankova LG, Dwyer DF, Yoshimoto E, et al. The cysteinyl leukotriene 3 receptor regulates expansion of IL-25-producing airway brush cells leading to type 2 inflammation. Sci Immunol 2018; 3.</a></li><li><a class="nounderline abstract_t">Liu T, Barrett NA, Kanaoka Y, et al. Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity. J Immunol 2018; 200:915.</a></li><li><a class="nounderline abstract_t">Pace S, Pergola C, Dehm F, et al. Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males. J Clin Invest 2017; 127:3167.</a></li><li><a class="nounderline abstract_t">In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130.</a></li><li><a class="nounderline abstract_t">Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233.</a></li><li><a class="nounderline abstract_t">Helgadottir A, Gretarsdottir S, St Clair D, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005; 76:505.</a></li><li><a class="nounderline abstract_t">Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23:290.</a></li><li><a class="nounderline abstract_t">Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 Suppl 2:S28.</a></li><li><a class="nounderline abstract_t">Van Sambeek R, Stevenson DD, Baldasaro M, et al. 5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000; 106:72.</a></li><li><a class="nounderline abstract_t">Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101:834.</a></li><li><a class="nounderline abstract_t">Hsieh FH, Lam BK, Penrose JF, et al. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C(4) synthase expression by interleukin 4. J Exp Med 2001; 193:123.</a></li><li><a class="nounderline abstract_t">Cowburn AS, Holgate ST, Sampson AP. IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. J Immunol 1999; 163:456.</a></li><li><a class="nounderline abstract_t">Rabinovitch N, Graber NJ, Chinchilli VM, et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol 2010; 126:545.</a></li><li><a class="nounderline abstract_t">Weiss JW, Drazen JM, Coles N, et al. Bronchoconstrictor effects of leukotriene C in humans. Science 1982; 216:196.</a></li><li><a class="nounderline abstract_t">Weiss JW, Drazen JM, McFadden ER Jr, et al. Comparative bronchoconstrictor effects of histamine, leukotriene C, and leukotriene D in normal human volunteers. Trans Assoc Am Physicians 1982; 95:30.</a></li><li><a class="nounderline abstract_t">Griffin M, Weiss JW, Leitch AG, et al. Effects of leukotriene D on the airways in asthma. N Engl J Med 1983; 308:436.</a></li><li><a class="nounderline abstract_t">Hamilton A, Faiferman I, Stober P, et al. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 1998; 102:177.</a></li><li><a class="nounderline abstract_t">Drazen JM. Asthma therapy with agents preventing leukotriene synthesis or action. Proc Assoc Am Physicians 1999; 111:547.</a></li><li><a class="nounderline abstract_t">O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997; 127:472.</a></li><li><a class="nounderline abstract_t">Rorke S, Jennison S, Jeffs JA, et al. Role of cysteinyl leukotrienes in adenosine 5'-monophosphate induced bronchoconstriction in asthma. Thorax 2002; 57:323.</a></li><li><a class="nounderline abstract_t">Brannan JD, Gulliksson M, Anderson SD, et al. Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur Respir J 2003; 22:491.</a></li><li><a class="nounderline abstract_t">Drazen JM, O'Brien J, Sparrow D, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146:104.</a></li><li><a class="nounderline abstract_t">Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167:528.</a></li><li><a class="nounderline abstract_t">Camargo CA Jr, Gurner DM, Smithline HA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol 2010; 125:374.</a></li><li><a class="nounderline abstract_t">Arm JP, O'Hickey SP, Hawksworth RJ, et al. Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine, and histamine. Am Rev Respir Dis 1990; 142:1112.</a></li><li><a class="nounderline abstract_t">Davidson AB, Lee TH, Scanlon PD, et al. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis 1987; 135:333.</a></li><li><a class="nounderline abstract_t">Christie PE, Schmitz-Schumann M, Spur BW, Lee TH. Airway responsiveness to leukotriene C4 (LTC4), leukotriene E4 (LTE4) and histamine in aspirin-sensitive asthmatic subjects. Eur Respir J 1993; 6:1468.</a></li><li><a class="nounderline abstract_t">Arm JP, O'Hickey SP, Spur BW, Lee TH. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989; 140:148.</a></li><li><a class="nounderline abstract_t">Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347:1493.</a></li><li><a class="nounderline abstract_t">Corrigan C, Mallett K, Ying S, et al. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 2005; 115:316.</a></li><li><a class="nounderline abstract_t">Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111:180.</a></li><li><a class="nounderline abstract_t">Cahill KN, Cui J, Kothari P, et al. Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial. Am J Respir Crit Care Med 2019; 200:704.</a></li><li><a class="nounderline abstract_t">Marom Z, Shelhamer JH, Bach MK, et al. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126:449.</a></li><li><a class="nounderline abstract_t">Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009; 206:2543.</a></li><li><a class="nounderline abstract_t">Mellor EA, Austen KF, Boyce JA. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med 2002; 195:583.</a></li><li><a class="nounderline abstract_t">Paruchuri S, Jiang Y, Feng C, et al. Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem 2008; 283:16477.</a></li><li><a class="nounderline abstract_t">Jiang Y, Borrelli LA, Kanaoka Y, et al. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 2007; 110:3263.</a></li><li><a class="nounderline abstract_t">Jiang Y, Kanaoka Y, Feng C, et al. Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. J Immunol 2006; 177:2755.</a></li><li><a class="nounderline abstract_t">Idzko M, Hammad H, van Nimwegen M, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 2007; 13:913.</a></li><li><a class="nounderline abstract_t">Barrett NA, Fernandez JM, Maekawa A, et al. Cysteinyl leukotriene 2 receptor on dendritic cells negatively regulates ligand-dependent allergic pulmonary inflammation. J Immunol 2012; 189:4556.</a></li><li><a class="nounderline abstract_t">Barrett NA, Rahman OM, Fernandez JM, et al. Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes. J Exp Med 2011; 208:593.</a></li><li><a class="nounderline abstract_t">Stelmach I, Bobrowska-Korzeniowska M, Majak P, et al. The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. Pulm Pharmacol Ther 2005; 18:374.</a></li><li><a class="nounderline abstract_t">Mjösberg JM, Trifari S, Crellin NK, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12:1055.</a></li><li><a class="nounderline abstract_t">Salimi M, Stöger L, Liu W, et al. Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines. J Allergy Clin Immunol 2017.</a></li><li><a class="nounderline abstract_t">von Moltke J, O'Leary CE, Barrett NA, et al. Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s. J Exp Med 2017; 214:27.</a></li><li><a class="nounderline abstract_t">Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341:989.</a></li><li><a class="nounderline abstract_t">Gauvreau GM, Parameswaran KN, Watson RM, O'Byrne PM. Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med 2001; 164:1495.</a></li><li><a class="nounderline abstract_t">Laitinen A, Lindqvist A, Halme M, et al. Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma. J Allergy Clin Immunol 2005; 115:259.</a></li><li><a class="nounderline abstract_t">Cummings HE, Liu T, Feng C, et al. Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J Immunol 2013; 191:5807.</a></li><li><a class="nounderline abstract_t">Liu T, Barrett NA, Kanaoka Y, et al. Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism. Mucosal Immunol 2019; 12:679.</a></li><li><a class="nounderline abstract_t">Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119:1059.</a></li><li><a class="nounderline abstract_t">Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133:424.</a></li><li><a class="nounderline abstract_t">Pearlman DS, Ostrom NK, Bronsky EA, et al. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 1999; 134:273.</a></li><li><a class="nounderline abstract_t">Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49:749.</a></li><li><a class="nounderline abstract_t">Lazarus SC, Wong HH, Watts MJ, et al. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1997; 156:1725.</a></li><li><a class="nounderline abstract_t">Diamant Z, Grootendorst DC, Veselic-Charvat M, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999; 29:42.</a></li><li><a class="nounderline abstract_t">Nelson H, Kemp J, Berger W, et al. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. Ann Allergy Asthma Immunol 2007; 99:178.</a></li><li><a class="nounderline abstract_t">Kubavat AH, Khippal N, Tak S, et al. A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma. Am J Ther 2013; 20:154.</a></li><li><a class="nounderline abstract_t">Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007; 61:663.</a></li><li><a class="nounderline abstract_t">Thalanayar Muthukrishnan P, Nouraie M, Parikh A, Holguin F. Zileuton use and phenotypic features in asthma. Pulm Pharmacol Ther 2020; 60:101872.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 21, 2017).</li><li class="breakAll">2023 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. www.ginasthma.org/2023-gina-main-report (Accessed on May 15, 2023).</li><li><a class="nounderline abstract_t">Dahlén SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:9.</a></li><li><a class="nounderline abstract_t">Barnes N, Thomas M, Price D, Tate H. The national montelukast survey. J Allergy Clin Immunol 2005; 115:47.</a></li><li><a class="nounderline abstract_t">Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487.</a></li><li><a class="nounderline abstract_t">Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002; 110:847.</a></li><li><a class="nounderline abstract_t">Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158:1213.</a></li><li><a class="nounderline abstract_t">Price DB, Swern A, Tozzi CA, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61:737.</a></li><li><a class="nounderline abstract_t">Lee MY, Lai YS, Yang KD, et al. Effects of montelukast on symptoms and eNO in children with mild to moderate asthma. Pediatr Int 2005; 47:622.</a></li><li><a class="nounderline abstract_t">Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119:1021.</a></li><li><a class="nounderline abstract_t">Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004; 92:641.</a></li><li><a class="nounderline abstract_t">Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994; 150:618.</a></li><li><a class="nounderline abstract_t">Kraft M, Cairns CB, Ellison MC, et al. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 2006; 130:1726.</a></li><li><a class="nounderline abstract_t">Miligkos M, Bannuru RR, Alkofide H, et al. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med 2015; 163:756.</a></li><li><a class="nounderline abstract_t">Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126:177.</a></li><li><a class="nounderline abstract_t">Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171:315.</a></li><li class="breakAll">Montelukast Package Insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf (Accessed on February 21, 2017).</li><li><a class="nounderline abstract_t">Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999; 14:12.</a></li><li><a class="nounderline abstract_t">Straub DA, Minocchieri S, Moeller A, et al. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 2005; 127:509.</a></li><li><a class="nounderline abstract_t">Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012; :CD002314.</a></li><li><a class="nounderline abstract_t">Zeiger RS, Bird SR, Kaplan MS, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005; 118:649.</a></li><li><a class="nounderline abstract_t">Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005; 116:360.</a></li><li><a class="nounderline abstract_t">Currie GP, Lee DK, Haggart K, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003; 167:1232.</a></li><li><a class="nounderline abstract_t">Allen-Ramey FC, Duong PT, Riedel AA, et al. Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline. Ann Allergy Asthma Immunol 2004; 93:373.</a></li><li><a class="nounderline abstract_t">Maspero JF, Dueñas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001; 17:96.</a></li><li><a class="nounderline abstract_t">Balkrishnan R, Nelsen LM, Kulkarni AS, et al. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis. J Asthma 2005; 42:35.</a></li><li><a class="nounderline abstract_t">Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364:1695.</a></li><li><a class="nounderline abstract_t">Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med 2005; 99:1263.</a></li><li><a class="nounderline abstract_t">Bukstein DA, Luskin AT, Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003; 90:543.</a></li><li><a class="nounderline abstract_t">Tan H, Sarawate C, Singer J, et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc 2009; 84:675.</a></li><li class="breakAll">Scottish Intercollegiate Guidelines Network (SIGN). British guideline on the management of asthma (2016). http://www.sign.ac.uk/pdf/SIGN153.pdf (Accessed on March 16, 2017).</li><li><a class="nounderline abstract_t">Phipatanakul W, Greene C, Downes SJ, et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003; 91:49.</a></li><li><a class="nounderline abstract_t">Ulrik CS, Diamant Z. Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing. Clin Exp Allergy 2010; 40:576.</a></li><li><a class="nounderline abstract_t">Sladek K, Dworski R, Soja J, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149:940.</a></li><li><a class="nounderline abstract_t">Gyllfors P, Dahlén SE, Kumlin M, et al. Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate. J Allergy Clin Immunol 2006; 118:78.</a></li><li><a class="nounderline abstract_t">Biernacki WA, Kharitonov SA, Biernacka HM, Barnes PJ. Effect of montelukast on exhaled leukotrienes and quality of life in asthmatic patients. Chest 2005; 128:1958.</a></li><li><a class="nounderline abstract_t">Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997; 17:3S.</a></li><li><a class="nounderline abstract_t">Vachier I, Kumlin M, Dahlén SE, et al. High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma. Respir Med 2003; 97:1225.</a></li><li><a class="nounderline abstract_t">Severien C, Artlich A, Jonas S, Becher G. Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma. Eur Respir J 2000; 16:588.</a></li><li><a class="nounderline abstract_t">Baumgartner RA, Martinez G, Edelman JM, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J 2003; 21:123.</a></li><li><a class="nounderline abstract_t">Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58:211.</a></li><li><a class="nounderline abstract_t">Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357:2007.</a></li><li><a class="nounderline abstract_t">American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175:235.</a></li><li><a class="nounderline abstract_t">Ye YM, Kim SH, Hur GY, et al. Addition of Montelukast to Low-Dose Inhaled Corticosteroid Leads to Fewer Exacerbations in Older Patients Than Medium-Dose Inhaled Corticosteroid Monotherapy. Allergy Asthma Immunol Res 2015; 7:440.</a></li><li><a class="nounderline abstract_t">Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma 2012; 49:530.</a></li><li><a class="nounderline abstract_t">Chauhan BF, Jeyaraman MM, Singh Mann A, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev 2017; 3:CD010347.</a></li><li><a class="nounderline abstract_t">Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), Cloutier MM, Baptist AP, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020; 146:1217.</a></li><li><a class="nounderline abstract_t">Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; 327:891.</a></li><li><a class="nounderline abstract_t">Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106:1088.</a></li><li><a class="nounderline abstract_t">Ringdal N, Eliraz A, Pruzinec R, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003; 97:234.</a></li><li><a class="nounderline abstract_t">Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103:1075.</a></li><li><a class="nounderline abstract_t">Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2014; :CD003137.</a></li><li><a class="nounderline abstract_t">Lee JH, Haselkorn T, Borish L, et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007; 132:1882.</a></li><li><a class="nounderline abstract_t">Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970.</a></li><li><a class="nounderline abstract_t">Stevens WW, Peters AT, Hirsch AG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2017; 5:1061.</a></li><li><a class="nounderline abstract_t">Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2015; 135:245.</a></li><li><a class="nounderline abstract_t">Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187.</a></li><li><a class="nounderline abstract_t">Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148:1447.</a></li><li><a class="nounderline abstract_t">Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94:1046.</a></li><li><a class="nounderline abstract_t">Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002; 32:1491.</a></li><li><a class="nounderline abstract_t">White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005; 95:330.</a></li><li><a class="nounderline abstract_t">Coreno A, Skowronski M, Kotaru C, McFadden ER Jr. Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. J Allergy Clin Immunol 2000; 106:500.</a></li><li><a class="nounderline abstract_t">Villaran C, O'Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 1999; 104:547.</a></li><li><a class="nounderline abstract_t">Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000; 132:97.</a></li><li><a class="nounderline abstract_t">Coreno A, Skowronski M, West E, et al. Bronchoprotective effects of single doses of salmeterol combined with montelukast in thermally induced bronchospasm. Chest 2005; 127:1572.</a></li><li><a class="nounderline abstract_t">Pearlman DS, van Adelsberg J, Philip G, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006; 97:98.</a></li><li><a class="nounderline abstract_t">Bisgaard H, Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003; 167:379.</a></li><li><a class="nounderline abstract_t">Brodlie M, Gupta A, Rodriguez-Martinez CE, et al. Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children. Cochrane Database Syst Rev 2015; :CD008202.</a></li><li><a class="nounderline abstract_t">Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233.</a></li><li><a class="nounderline abstract_t">Rossi A, Roviezzo F, Sorrentino R, et al. Leukotriene-mediated sex dimorphism in murine asthma-like features during allergen sensitization. Pharmacol Res 2019; 139:182.</a></li><li><a class="nounderline abstract_t">Sessa M, Mascolo A, D'Agostino B, et al. Relationship Between Gender and the Effectiveness of Montelukast: An Italian/Danish Register-Based Retrospective Cohort Study. Front Pharmacol 2018; 9:844.</a></li><li><a class="nounderline abstract_t">Rundell KW, Spiering BA, Baumann JM, Evans TM. Bronchoconstriction provoked by exercise in a high-particulate-matter environment is attenuated by montelukast. Inhal Toxicol 2005; 17:99.</a></li><li><a class="nounderline abstract_t">Gong H Jr, Linn WS, Terrell SL, et al. Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide. Chest 2001; 119:402.</a></li><li><a class="nounderline abstract_t">Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006; 100:1952.</a></li><li><a class="nounderline abstract_t">Virchow JC, Mehta A, Ljungblad L, Mitfessel H. A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients. J Asthma 2010; 47:986.</a></li><li><a class="nounderline abstract_t">Fauler J, Frölich JC. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 1997; 27:43.</a></li><li><a class="nounderline abstract_t">Price D, Popov TA, Bjermer L, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol 2013; 131:763.</a></li><li class="breakAll">Drugs and Lactation Database (LactMed). https://www.ncbi.nlm.nih.gov/books/NBK501488/#LM600.Drug_Levels_and_Effects (Accessed on February 22, 2021).</li><li class="breakAll">US Food and Drug Administration. FDA Requires Stronger Warning About Risk of Neuropsychiatric Events Associated with Asthma and Allergy Medication Singulair and Generic Montelukast. https://www.fda.gov/news-events/press-announcements/fda-requires-stronger-warning-about-risk-neuropsychiatric-events-associated-asthma-and-allergy (Accessed on March 05, 2020).</li><li><a class="nounderline abstract_t">Druss B, Pincus H. Suicidal ideation and suicide attempts in general medical illnesses. Arch Intern Med 2000; 160:1522.</a></li><li><a class="nounderline abstract_t">Philip G, Hustad C, Noonan G, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124:691.</a></li><li><a class="nounderline abstract_t">Schumock GT, Stayner LT, Valuck RJ, et al. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. J Allergy Clin Immunol 2012; 130:368.</a></li><li><a class="nounderline abstract_t">Philip G, Hustad CM, Malice MP, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124:699.</a></li><li><a class="nounderline abstract_t">Glockler-Lauf SD, Finkelstein Y, Zhu J, et al. Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case-Control Study. J Pediatr 2019; 209:176.</a></li><li><a class="nounderline abstract_t">Law SWY, Wong AYS, Anand S, et al. Neuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review. Drug Saf 2018; 41:253.</a></li><li><a class="nounderline abstract_t">Paljarvi T, Forton J, Luciano S, et al. Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation. JAMA Netw Open 2022; 5:e2213643.</a></li><li><a class="nounderline abstract_t">Park JS, Cho YJ, Yun JY, et al. Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Jordan A, Toennesen LL, Eklöf J, et al. Psychiatric Adverse Effects of Montelukast-A Nationwide Cohort Study. J Allergy Clin Immunol Pract 2023; 11:2096.</a></li><li><a class="nounderline abstract_t">Watkins PB, Dube LM, Walton-Bowen K, et al. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf 2007; 30:805.</a></li><li class="breakAll">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK548397/ (Accessed on February 22, 2021).</li><li><a class="nounderline abstract_t">Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008; 63:883.</a></li><li><a class="nounderline abstract_t">Bibby S, Healy B, Steele R, et al. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010; 65:132.</a></li><li><a class="nounderline abstract_t">Terashima T, Amakawa K, Matsumaru A, Yamaguchi K. Correlation between cysteinyl leukotriene release from leukocytes and clinical response to a leukotriene inhibitor. Chest 2002; 122:1566.</a></li><li><a class="nounderline abstract_t">Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12:565.</a></li><li><a class="nounderline abstract_t">Tanaka H, Saito T, Kurokawa K, et al. Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. Allergy 1999; 54:489.</a></li><li><a class="nounderline abstract_t">Cai C, Yang J, Hu S, et al. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung 2007; 185:105.</a></li><li><a class="nounderline abstract_t">Drazen JM, Yandava CN, Dubé L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168.</a></li><li><a class="nounderline abstract_t">Currie GP, Lima JJ, Sylvester JE, et al. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol 2003; 56:422.</a></li><li><a class="nounderline abstract_t">Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17:189.</a></li><li><a class="nounderline abstract_t">Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009; 19:129.</a></li><li><a class="nounderline abstract_t">Dahlin A, Litonjua A, Irvin CG, et al. Genome-wide association study of leukotriene modifier response in asthma. Pharmacogenomics J 2016; 16:151.</a></li><li><a class="nounderline abstract_t">Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98:528.</a></li><li><a class="nounderline abstract_t">Gauvreau GM, Boulet LP, FitzGerald JM, et al. A dual CysLT1/2 antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma. Allergy 2016; 71:1721.</a></li><li><a class="nounderline abstract_t">Laidlaw TM, Boyce JA. Aspirin-Exacerbated Respiratory Disease--New Prime Suspects. N Engl J Med 2016; 374:484.</a></li></ol></div><div id="topicVersionRevision">Topic 553 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8245774" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8444871" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7628486" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cloning and characterization of the human leukotriene A4 hydrolase gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12949533" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8052639" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477727" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Role of lipid mediators and control of lymphocyte responses in type 2 immunopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3995081" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Purification and characterisation of leukotriene A4 hydrolase from rat neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6322626" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Leukotriene B4 production by the human alveolar macrophage: a potential mechanism for amplifying inflammation in the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029019" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Leukotriene B4 release from mast cells in IgE-mediated airway hyperresponsiveness and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30352167" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Leukotriene A4 Hydrolase Activation and Leukotriene B4 Production by Eosinophils in Severe Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9177352" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11006272" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22542839" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : LTB4 is a signal-relay molecule during neutrophil chemotaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12949531" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814727" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23573812" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : IL-13-producing BLT1-positive CD8 cells are increased in asthma and are associated with airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28053970" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Leukotriene B4 levels in sputum from asthma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19647860" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6324182" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19124755" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dectin-2 recognition of house dust mite triggers cysteinyl leukotriene generation by dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734767" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28887514" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dormant 5-lipoxygenase in inflammatory macrophages is triggered by exogenous arachidonic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262771" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7531878" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B2 and leukotriene C4 cooperative synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22227382" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Platelet activation, P-selectin, and eosinophilβ1-integrin activation in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953256" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Airway brush cells generate cysteinyl leukotrienes through the ATP sensor P2Y2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32160525" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tuft-Cell-Derived Leukotrienes Drive Rapid Anti-helminth Immunity in the Small Intestine but Are Dispensable for Anti-protist Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11463821" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Disruption of gamma-glutamyl leukotrienase results in disruption of leukotriene D(4) synthesis in vivo and attenuation of the acute inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6293969" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2174886" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Leukotriene E4 elimination and metabolism in normal human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2564113" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1850964" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22925317" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cysteinyl leukotriene receptors, old and new; implications for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533366" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10808172" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391245" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Characterization of the human cysteinyl leukotriene CysLT1 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208650" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14519144" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29518425" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22174450" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388011" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23688412" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438743" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10851239" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Characterization of the human cysteinyl leukotriene 2 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23504326" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27185938" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30291131" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The cysteinyl leukotriene 3 receptor regulates expansion of IL-25-producing airway brush cells leading to type 2 inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282304" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28737505" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062372" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14770184" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15640973" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10970818" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10992553" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10887308" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : 5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466979" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136826" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C(4) synthase expression by interleukin 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10384149" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20816189" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7063880" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bronchoconstrictor effects of leukotriene C in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7182983" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparative bronchoconstrictor effects of histamine, leukotriene C, and leukotriene D in normal human volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823253" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of leukotriene D on the airways in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9723658" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10591083" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Asthma therapy with agents preventing leukotriene synthesis or action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9313005" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Antileukotrienes in the treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923550" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Role of cysteinyl leukotrienes in adenosine 5'-monophosphate induced bronchoconstriction in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14516140" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Evidence of mast cell activation and leukotriene release after mannitol inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1320817" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Recovery of leukotriene E4 from the urine of patients with airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12456380" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A randomized controlled trial of intravenous montelukast in acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159247" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2173457" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine, and histamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3028218" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8112440" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Airway responsiveness to leukotriene C4 (LTC4), leukotriene E4 (LTE4) and histamine in aspirin-sensitive asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2546469" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421891" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696087" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12532116" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30978291" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7125334" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19822647" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877481" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18411276" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17693579" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16920908" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632526" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23002438" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cysteinyl leukotriene 2 receptor on dendritic cells negatively regulates ligand-dependent allergic pulmonary inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357742" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939317" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21909091" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28115217" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011865" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8096945" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Leukotriene E4 and granulocytic infiltration into asthmatic airways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704602" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696079" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24244016" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30664709" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239223" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738728" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10064661" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8091318" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9412547" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051701" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17718106" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22926233" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17394438" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31841698" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Zileuton use and phenotypic features in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31841698" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Zileuton use and phenotypic features in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31841698" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Zileuton use and phenotypic features in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779723" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637546" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The national montelukast survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10075616" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12464949" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Effects of montelukast and beclomethasone on airway function and asthma control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9625400" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677244" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354213" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Effects of montelukast on symptoms and eNO in children with mild to moderate asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11296164" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15237766" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8087328" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166989" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26390230" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9027267" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15542792" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15542792" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10489822" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705989" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592685" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15922697" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16061590" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12456382" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15521374" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11759189" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15801326" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21542741" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Leukotriene antagonists as first-line or add-on asthma-controller therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16140227" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Adherence to asthma controller medication regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775136" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648384" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Impact of asthma controller medications on clinical, economic, and patient-reported outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648384" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Impact of asthma controller medications on clinical, economic, and patient-reported outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12877449" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20128823" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8143059" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16815141" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236841" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Effect of montelukast on exhaled leukotrienes and quality of life in asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017783" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Arachidonic acid metabolites: mediators of inflammation in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14635978" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11106196" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12570120" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612295" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438132" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16998094" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26122504" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Addition of Montelukast to Low-Dose Inhaled Corticosteroid Leads to Fewer Exacerbations in Older Patients Than Medium-Dose Inhaled Corticosteroid Monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551116" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28301050" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33280709" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14563743" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112891" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12645830" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10359889" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24459050" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079222" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275362" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286156" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25218285" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563738" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256883" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7798537" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12372130" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16279562" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10984370" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482826" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10644288" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888830" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Bronchoprotective effects of single doses of salmeterol combined with montelukast in thermally induced bronchospasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16892789" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406832" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26482324" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696076" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Characterization of within-subject responses to fluticasone and montelukast in childhood asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30468889" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Leukotriene-mediated sex dimorphism in murine asthma-like features during allergen sensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30116192" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Relationship Between Gender and the Effectiveness of Montelukast: An Italian/Danish Register-Based Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764487" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Bronchoconstriction provoked by exercise in a high-particulate-matter environment is attenuated by montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11171715" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626955" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Efficacy and safety of montelukast in adults with asthma and allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20858152" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041376" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Cigarette smoking stimulates cysteinyl leukotriene production in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380218" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Effect of montelukast for treatment of asthma in cigarette smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380218" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Effect of montelukast for treatment of asthma in cigarette smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380218" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Effect of montelukast for treatment of asthma in cigarette smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10826468" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Suicidal ideation and suicide attempts in general medical illnesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815114" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Reports of suicidality in clinical trials of montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22698520" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815116" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Analysis of behavior-related adverse experiences in clinical trials of montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30905424" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29076063" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Neuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35608857" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35595323" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36948487" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Psychiatric Adverse Effects of Montelukast-A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17722971" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17722971" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18492740" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147592" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12426254" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Correlation between cysteinyl leukotriene release from leukocytes and clinical response to a leukotriene inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360108" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10380781" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17393242" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369259" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12968987" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17460547" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19151602" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26031901" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Genome-wide association study of leukotriene modifier response in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8828530" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27444660" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : A dual CysLT1/2 antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26840139" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
